Economic evaluation of second measles containing vaccine (MCV) dose: a systematic review of available evidence.
Expert Rev Vaccines
; 23(1): 655-673, 2024.
Article
in En
| MEDLINE
| ID: mdl-38924461
ABSTRACT
INTRODUCTION:
The global measles incidence has decreased from 145 to 49 cases per 1 million population from 2000 to 2018, but evaluating the economic benefits of a second measles-containing vaccine (MCV2) is crucial. This study reviewed the evidence and quality of economic evaluation studies to guide MCV2 introduction.METHODS:
The systematic review of model-based economic evaluation studies was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search yielded 2231 articles, with 876 duplicates removed and 1355 articles screened, with nine studies included for final analysis.RESULTS:
Six studies reported a positive benefit-cost ratio with one resulting in net savings of $11.6 billion, and two studies estimated a 2-dose MMR vaccination program would save $119.24 to prevent one measles case, and a second dose could prevent 9,200 cases at 18 months, saving $548.19 per case. The most sensitive variables were the discount rate and vaccination administration cost.CONCLUSIONS:
Two MCV doses or a second opportunity with an additional dose of MCV were highly cost-beneficial and resulted in substantial cost savings compared to a single routine vaccine. But further research using high-quality model-based health economic evaluation studies of MCV2 should be made available to decision-makers. PROSPERO REGISTRATION CRD42020200669.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Measles Vaccine
/
Cost-Benefit Analysis
/
Immunization Programs
/
Measles
Limits:
Humans
Language:
En
Journal:
Expert Rev Vaccines
Journal subject:
ALERGIA E IMUNOLOGIA
Year:
2024
Document type:
Article
Affiliation country: